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Abstract
Background: Creatinine clearance (CrCl) based on 24 h urine collection is an established method to determine
glomerular filtration rate (GFR). However, its measurement is cumbersome and the results are frequently inaccurate.
The aim of this study was to develop an alternative method to predict CrCl and urinary protein excretion based on
plasma creatinine and the quantification of muscle mass through bioimpedance analysis (BIA).
Methods: In 91 individuals with normal and impaired renal function CrCl was measured from 24 h urine excretion
and plasma creatinine concentration. A model to predict 24 h-creatininuria was developed from various
measurements assessing muscle mass such as body cell mass (BCM) and fat free mass (FFM) obtained by BIA,
skinfold caliper and other techniques (training group, N = 60). Multivariate regression analysis was performed to
predict 24 h-creatininuria and to calculate CrCl. A validation group (N = 31) served to compare predicted and
measured CrCl.
Results: Overall (accuracy, bias, precision, correlation) the new BIA based prediction model performed substantially
better compared with measured CrCl (P15 = 87 %, bias = 0, IQR of differences = 7.9 mL/min/1.73 m
2, R = 0.972)
versus established estimation formulas such as the 4vMDRD (P15 = 26 %, bias = -8.3 mL/min/1.73 m
2, IQR = 13.7 mL/
min/1.73 m2, R = 0.935), CKD-EPI (P15 = 29 %, bias = -7.0 mL/min/1.73 m
2, IQR = 12.1 mL/min/1.73 m2, R = 0.932,
Cockcroft-Gault equations (P15 = 55 %, bias = -4.4 mL/min/1.73 m
2, IQR = 9.0 mL/min/1.73 m2, R = 0.920). The
superiority of the new method over established prediction formulas was most obvious in a subgroup of individuals
with BMI > 30 kg/m2 and in a subgroup with CrCl > 60 mL/min/1.73 m2. Moreover, 24 h urinary protein excretion
could be estimated accurately by normalization with 24 h-creatininuria derived from BIA based BCM.
Conclusion: Prediction of CrCl based on estimated urinary creatinine excretion determined from measurement of
BCM by BIA technique is both accurate and convenient to quantify renal function in normal and diseased states.
This new method may become particularly helpful for the evaluation of patients with borderline renal insufficiency
and/or with abnormal body composition.
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Background
Glomerular filtration rate (GFR), as a measure of excre-
tory kidney function is an important parameter to make
diagnostic or therapeutic decisions as well as a tool to
monitor the course of kidney disease. The gold standards
to measure GFR are inulin or radioisotope clearance
techniques. GFR, however, can also be determined fairly
accurate and non-invasive by measuring creatinine clear-
ance, which requires a 24 h urine collection. This method,
however, has been replaced widely in clinical practice by
estimating GFR using established formulas due to simpli-
city and ease of use [1, 2].
For GFR estimation in adult patients the validated
CKD-EPI and the four-variables-MDRD (4vMDRD) for-
mulas are used most often, whereas the Cockcroft-Gault
formula can be applied to estimate creatinine clearance
(CrCl). For a range of GFR around and beyond 60 mL/
min/1.73 m2 the 4vMDRD-formula is less accurate than
the CKD-EPI formula. The Cockcroft-Gault formula on
the other hand is less precise in predicting renal
function in cases of advanced kidney failure. More-
over, this formula overestimates GFR slightly because
it determines CrCl [3–8].
All the prediction equations share the common feature
to be based on plasma creatinine (PCr), whose produc-
tion depends mainly on muscle mass, which is not incor-
porated in the formulas mentioned before. Therefore, in
patients with very high or low muscle mass, the estima-
tions are often imprecise [9]. Besides, the formulas are
not validated for all situations of clinical practice. For
example, the CKD-EPI formula is not validated for ado-
lescents below the age of 18 years or for pregnant
women, whereas the 4vMDRD-formula is not validated
for the very old (beyond 85 years). Both formulas were
developed from cohorts consisting of mainly Caucasians
or Blacks with uncertain accuracy in other ethnical
groups [10–14]. Moreover, in normal to mild impairment
of kidney function, the estimations are highly scattered
compared to gold standard methods [6, 15, 16]. Thus, in
many situations, it is still more reliable to measure CrCl in
order to accurately assess a patient’s kidney function than
to rely only on the estimation formulas.
An alternative approach to renal function determination
by either 24 h urine collection, radioisotope methods or
estimation formulas could be the incorporation of mea-
sured muscle mass into the calculation of CrCl. Several
methods to analyze tissue distribution are available. Body
composition can be determined according to its com-
partments of fat mass and lean body mass by radio-
logical techniques of dual x-ray absorptiometry (DXA)
or bioimpedance analysis (BIA) [17, 18]. An older
method relies on prediction of body fat mass and fat
free mass by measuring subcutaneous skin folds in a
standardized manner [19, 20].
The aim of our study was to elaborate and validate a
method based on parameters obtained by BIA to predict
CrCl as a measure of excretory renal function without
timed urine collection and on the basis of previously pub-
lished studies by Donadio et al. [21–23]. Additionally, we
wanted to evaluate whether other methods of muscle
mass determination – i.e. skin fold based measurements,
mid arm muscle circumference (MAMC) or other an-
thropometric parameters such as BMI or waist-hip ratio –
may be used alternatively or complementary for predictive
models. Furthermore, the developed approach to deter-
mine creatinine excretion could be used to estimate 24 h
urinary protein excretion, which is a cornerstone to diag-
nose, classify and monitor proteinuric nephropathies.
Methods
Study population
A total of 91 individuals (85 patients consecutively pre-
senting in our outpatient clinic and 6 healthy volunteers)
were included in this study. The cohort was divided into
a ‘training group’, formed by the first 60 individuals
including the 6 healthy volunteers (42 male, 18 female),
and a ‘validation group’ (15 male, 16 female). All partici-
pants were required to have a stable kidney function, as
could be verified by checking plasma creatinine based
on local medical records on file or from referral docu-
ments. The nephrological diagnoses or reasons for referral
consisted of: Chronic kidney disease caused by vascular
nephropathy (N = 24), diabetic nephropathy (10), glomer-
ulonephritis (13), polycystic kidney disease (7) and various
causes (18), patients with kidney transplants (3), nephro-
lithiasis workup (10), and six healthy volunteers. All
laboratory measurements were conducted as part of the
diagnostic routine. Similarly, determination of body
composition is an integral component of the workup of
patients with kidney disease at our institution.
Anthropometry, lab analyses
In all participants, CrCl was determined based on a
single 24 h urine collection and plasma creatinine meas-
urement. The absolute value for measured CrCl (24hU-
CrCl) was normalized for estimated body surface area
(according to DuBois formula). All individuals received
detailed instructions on correct 24 h urine sampling. On
the day of consultation, the following anthropometric
measurements were performed: Weight, height, waist, hip
circumference and upper arm circumference; standardized
skin folds were measured with a commercially available
caliper instrument. Lean body mass (LBM) was calculated
using the skin fold measurements according to the
equation of Durnin and Womersley [19]. Midarm muscle
circumference (MAMC) was determined using the
formula MAMC [cm] =MAC [cm] - 0.314 x TSF [mm].
Finally, waist/hip-ratio was calculated [24, 25]. At the
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same time, a body impedance analysis using the single
frequency body impedance device “BIA 101” (Akern®) was
conducted according to manufacturer’s instructions
[26–28]. This device delivers impulses and alternating
current of 0.8 mA with a frequency of 50 kHz. To
measure the resistance (R) and reactance (Xc), two
electrodes have to be placed on each extremity of one
body half of the patient in supine position. Fat free
mass (FFM) and body cell mass (BCM) were obtained
from input of the bioimpedance data, body weight
and height as well as gender by a specific software
(Bodygram 3.0®). Additionally, FFM was also deter-
mined by a commercially available handheld BIA
technology device (Omron HBF 306 Body Logic Pro
Body Fat Analyzer®).
After venipuncture and blood centrifugation plasma
creatinine (PCr) was determined in the local labora-
tory according to the Jaffé method (CREJ2®, Roche
Diagnostics). In each individual’s collection urine creatin-
ine was determined and creatinine clearances were calcu-
lated. In addition, in 36 out of the 91 participants the total
amount of protein was determined and protein and
creatinine were measured from a spot urine sample. For
both quantifications the same turbidimetric method was
used (TPUC3®, Roche Diagnostics) on a Cobas®, Roche
Diagnostics, platform.
Statistical analyses, model development
The prediction rule for estimating creatinine clearance
based on anthropometric data was derived in three steps.
First, a multivariate regression model was developed to
predict 24 h-creatininuria (24hU-Cr) obtained from
urine collection. Second, 24 h-creatininuria determined
by this regression model was used to calculate the model
based creatinine clearance (mCrCl) according to the equa-
tion mCrCl =m24hU-Cr [mmol]/PCr [μmol/L]/1440
[min]. After adjusting for the different dimensions of the
enumerator (mmol) and the denominator (μmol), the re-
sult in L/min was multiplied by factor 1000, to receive the
usual clearance unit mL/min (analogously to the calcula-
tion of CrCl from 24 h urine collection). For ease of com-
parison, absolute values of mCrCl were normalized for
body surface area (BSA) (according to the DuBois
formula). Finally, the prediction model was evaluated in a
"validation group”. In order to assess the performance of
each method to estimate GFR or CrCl, correlation
analyses and a modified Bland-Altman plot between
measured CrCl from timed urine collection (24hU-CrCl)
and the various GFR and CrCl estimation formulas
(4vMDRD, CKD-EPI, Cockcroft-Gault formula), as well as
the CrCl calculated from the BIA-BCM based model
24 h-creatininuria (mCrCl) were applied [29]. Besides, the
following three parameters were used to compare between
the mentioned estimation methods and 24hU-CrCl: bias
(median difference between GFR resp. CrCl estimate
and 24hU-CrCl) and absolute bias (median difference
between │GFR resp. CrCl estimate − 24hU-CrCl│); pre-
cision (IQR and P25, P75 of differences between GFR
resp. CrCl estimate and 24hU-CrCl); accuracy (absolute
number and percentage of the estimates that were within
15 % range (P15) and/or 30 % range of 24hU-CrCl (P30)).
The Wilcoxon test and the McNemar test were used,
where applicable, to compare the estimation methods
with measured CrCl regarding stastically significant
differences of GFR results and accuracy values,
respectively.
In addition, for the 36 patients in whom the
amount of urinary proteins were quantified, we calcu-
lated 24 h urinary protein excretion by extrapolation
of the single spot specimen urinary protein/creatinine
ratio (UPCR) using the new model based 24 h-creati-
ninuria according to pPU =m24hU-Cr x UPCR. The
extrapolated values of urinary protein excretion and
the protein/creatinine ratios (with and without correc-
tion for body surface) were compared to the amounts
obtained from 24 h protein excretion by correlation
analysis and modified Bland-Altman-analysis. Add-
itionally, bias (median difference between pPU and
measured 24hU-PU), precision (IQR and P25, P75 of
differences between pPU method and measured
24hU-PU), accuracy (absolute number and percentage
of pPU values that lied within range 15 % (P15), and/
or 30 % range of measured 24hU-PU (P30) were
calculated.
All measurements in patients were performed as
part of routine examinations. Healthy volunteers gave
verbal informed consent on file to participate in the
measurements. The study protocol is in accordance
with and was formally approved by the institutional
review board (ethics committee of the Canton of
Zurich).
All analyses were conducted using the Statistical
Package for the Social Sciences (SPSS 19.0, SPSS,
Chicago, Ill., USA), Medcalc for Windows (Medcalc
Version 13.0, MedCalc Software, Ostend, Belgium)
was used for the figures.
Results
Patient characteristics are listed in Tables 1 and 2 for the
training and validation group respectively. In the
training group significant correlations with a Pearson’s
correlation coefficient (R) beyond 0.5 with 24-h urine
creatinine (24hU-Cr) excretion were detected for the
following parameters: FFM and BCM detected by
whole body bioimpedance analysis, FFM obtained by
Omron® BIA handheld device as well as for body
weight, body height, estimated body surface area and lean
body mass calculated from skin fold measurements. The
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correlation coefficients of each recorded parameter
with 24hU-Cr are shown in Table 3. The best cor-
relation with R = 0.896 was observed with BCM
measured by whole body bioimpedance analysis using
“BIA 101” (Akern®).
The set of all measured parameters mentioned above
having a correlation coefficient > 0.5 (see Table 3) was
then entered into a stepwise multivariate linear
regression model, in order to predict 24 h-creatini-
nuria (m24hU-Cr). In addition, the dichotomous
variable “gender” was included into the analysis
(“male” = 2, “female” = 1). The best model to predict
24-h urinary creatinine excretion consisted of only
two variables, namely body cell mass determined by
BIA and gender. This model had a coefficient of
determination (R2) of 0.81.
Table 1 Patient characteristics training group (N = 60)
Mean ± SD Median (P25, P75) Minimum, Maximum
Age; y 53 ± 16 56 (38, 64) 23, 83
Plasma creatinine; μmol/L 196.0 ± 157.0 137 (93.0, 258.0) 60.0, 831.0
24hU Creatinine; mmol 13.68 ± 4.22 13.6 (10.9, 16.4) 5.46, 25.10
24hU-CrCl; mL/min/1.73 m2 61.7 ± 34.9 55.0 (28.7, 90.3) 11.5, 136.0
eCrCl (Cockcroft-Gault); mL/min/1.73 m2 58.6 ± 37.2 52.4 (27.6, 78.6) 10.5, 175.7
eGFR (4vMDRD); mL/min/1.73 m2 47.6 ± 28.9 43.0 (22.8, 70.5) 6.0, 124.0
eGFR (CKD-EPI); mL/min/1.73 m2 51.1 ± 32.0 44.0 (23.3, 74.0) 6.0, 120.0
Body weight; kg 83.6 ± 21.2 78.7 (70.0, 94.3) 49.3, 154.6
Body height; cm 173 ± 9 174.5 (167.0, 180.3) 154, 192
BMI kg/m2 28.1 ± 6.8 25.8 (23.1, 31.2) 18.6, 56.8
Body Surface Area; m2 1.99 ± 0.27 1.97 (1.83, 2.13) 1.49, 2.66
BIA Free Fat Mass; kg 57.8 ± 12.6 57.1 (48.5, 67.2) 31.6, 93.1
BIA Body Cell Mass; kg 29.3 ± 8.2 28.3 (23.1, 34.7) 11.6, 52.5
Abdominal circumference; cm 101 ± 18 98 (89, 113) 72, 146
Hip circumference; cm 103 ± 13 102 (95, 110) 80, 147
Waist/hip ratio 0.98 ± 0.09 0.98 (0.93, 1.03) 0.75, 1.13
MAMC; cm 27.8 ± 4.0 27.7 (25.1, 30.2) 21.5, 40.5
LBM (skinfolds); kg 56.9 ± 11.7 57.4 (48.7, 65.3) 35.0, 88.2
Table 2 Patient characteristics validation group (N = 31)
Mean ± SD Median (P25, P75) Minimum, Maximum
Age; y 57 ± 16 57 (47, 69) 21, 82
Plasma creatinine; μmol/L 174.6 ± 100.1 157 (87.5, 222.5) 68.0, 373.0
Creatinine, 24hU; mmol 11.30 ± 3.42 11.3 (8.73, 14.50) 6.54, 17.80
CrCl; mL/min/1.73 m2 58.4 ± 37.5 44.0 (26.7, 89.8) 14.2, 137.0
eCrCl (Cockcroft-Gault); mL/min/1.73 m2 54.6 ± 35.2 37.9 (36.4, 86.6) 11.1, 201.1
eGFR (4vMDRD); mL/min/1.73 m2 49.0 ± 32.3 34.0 (20.5, 78.5) 10.0, 115.0
eGFR (CKD-EPI); mL/min/1.73 m2 52.0 ± 36.2 37.0 (20.5, 84.0) 10.0, 128.0
Body weight; kg 80.5 ± 13.7 76.4 (71.7, 85.3) 51.4, 113.4
Body height; cm 167 ± 10 167 (160, 173) 147, 187
BMI kg/m2 28.70 ± 5.3 27.5 (25.2, 29.8) 20.1, 45.4
Body Surface Area; m2 1.81 ± 0.61 1.88 (1.73, 2.01) 1.51, 2.25
BIA Free Fat Mass; kg 54.0 ± 11.3 50.0 (44.3, 57.0) 36.9, 91.2
BIA Body Cell Mass; kg 25.2 ± 6.3 24.4 (19.1, 30.1) 14.2, 37.7
Abdominal circumference; cm 104 ± 11 103 (94, 108) 91, 115
Hip circumference; cm 99 ± 13 100 (95, 104) 68, 112
Waist/hip ratio 0.99 ± 0.12 0.98 (0.95, 1.02) 0.74, 1.13
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The model resulting from the multivariate linear re-
gression analysis is expressed by the following formula:
m24hU−Cr mmol½  ¼ 2:1 þ 0:43
 BIA−BCM kg½ −0:92
 Gender f ¼ 1;m ¼ 2½ ;
R ¼ 0:899; SEE ¼ 1:9
Finally, to obtain an estimation of excretory kidney
function, the model based 24 h-creatininuria (m24hU-
Cr) was entered into the equation for creatinine clear-
ance (mCrCl =m24hU-Cr/PCr/1440 min).
In the training group, this model performed quite well
to predict CrCl, having a correlation with measured
CrCl of R = 0.970 (p < 0.001), SEE = 8.7 mL/min/1.73 m2,
where the median difference was 7.4 mL/min/1.73 m2,
and IQR 16.4 mL/min/1.73 m2 (see Table 4). In the
validation group, the model derived from the training
group still correlated strongly with measured CrCl
(R = 0.972, p < 0.001, SEE = 8.8 mL/min/1.73 m2;
Table 5, Fig. 1). In contrast, GFR values obtained
from the 4vMDRD and CKD-EPI formulas corre-
sponded clearly less with measured CrCl (R = 0.935,
p < 0.001, SEE = 11.4 mL/min/1.73 m2, and R = 0.932,
p < 0.001, SEE = 13.0 mL/min/1.73 m2, respectively).
Similarly, correlation of the Cockcroft-Gault equation
was even lower for 24hU-CrCl (R = 0.920, p < 0.001,
SEE = 14.2 mL/min/1.73 m2). The median difference
between measured CrCl and the prediction method
of excretory kidney function was lowest for the BCM
based model mCrCl (bias = 0, absolute bias = 4.4,
IQR = 7.9 mL/min/1.73 m2). In contrast, bias, abso-
lute bias and precision for 4vMDRD, CKD-EPI and
Cockcroft-Gault (CG) were clearly worse with -8.3,
8.9, IQR = 13.7 mL/min/1.73 m2 (median fractional
prediction error of 21.8 %); -7.0, 7.2, IQR = 12.1,
7.2 mL/min/1.73 m2 (19.8 %); and -4.4, 7.1, IQR =
9.0, 7.1 mL/min/1.73 m2 (7.0 %), respectively (Table 5,
Fig. 2). Statistically significant differences for eGFR
between 4vMDRD and CKD-EPI vs. 24hU-CrCl (p <
0.001) and CG-CrCl vs. 24hU-CrCl (p = 0.01), but
not between the new BCM derived model and 24hU-
CrCl (p = 0.86), were shown. Regarding accuracy, the
BCM derived model showed a significantly better
performance in the most important category P15. The
results of correlation, bias, precision and accuracy
considering different subgroups within the validation
group according to gender, mCrCl or BMI are shown
in Table 5. The better performance of the BCM
based model over the other prediction methods is
most obvious for 24hU-CrCl > 60 mL/min/1.73 m2
and for BMI > 30 kg/m2 (involving 4 individuals with
a BMI ≤ 34, 2 with a BMI of 35 and 2 with a BMI >
35 kg/m2, the maximum being 45.4 kg/m2), both
with regard to correlation and to accuracy, but also
to precision as an indicator of dispersion of the pre-
diction methods (see Table 5).
In the case of one specific female patient suffering
from chronic autoimmune disease, medically examined
for proteinuric nephropathy, the BCM based model
performed overwhelmingly better than the comparator
prediction methods (see Fig. 1). Unlike the other sub-
jects in the study, this patient was rather young
(21 years), had a high BMI (35.1 kg/m2), and normal
measured CrCl of 83.5 mL/min/1.73 m2 with a plasma
creatinine in the “low normal range”. Regarding her BIA
values, we observed a rather low ratio of BCM to total
body weight (0.25). Excluding this “outlier” case from
the analyses resulted in a convergence of the correlation
parameters R and SEE, without substantially affecting
both accuracy and precision analyses substantially (see
Table 6). This finding applied for the unstratified
Table 3 Bivariate correlation analysis between 24 h-creatininuria and various variables











24hU-Cr R (Pearson) −0.374 0.195 0.794 0.896 0.780 0.561 0.631 0.323 0.647 0.317 0.696 0.483
P (2-sided) 0.003 0.136 0.000 0.000 0.000 0.000 0.000 0.012 0.000 0.015 0.000 0.000










P15 (%) P30 (%)
All subjects (N = 60) mCrCl 0.970*** 8.7 7.4 8.5 16.4 (1.1, 17.5) 48 (80)a 56 (93)bcd
4vMDRD 0.930*** 13.1 −11.7 12.10 13.6 (-19.6, -5.9) 15 (25) 37 (62)
CKD-EPI 0.950*** 10.7 −10.2 10.4 10.6 (-15.5, -4.9) 21 (35) 45 (75)
CG-CrCl 0.840*** 19.3 −4.4 9.2 14.2 (-11.2, 3.0) 26 (43) 51 (85)
***p < 0.001
†displayed in mL/min/1.73 m2;
ap < 0.001 vs the three other methods; bp = 0.001 vs 4vMDRD; cp < 0.05 vs CKD-EPI; dp = 0.18 vs CG
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validation group as well as the respective BMI (>30), and
CrCl strata (24hU-CrCl > 60 ml/min/1.73 m2).
Calculated 24 h urinary protein excretion (N = 36)
derived from spot UPCR and modified by BCM based
24 h-creatininuria (BCM based pPU) showed a high
correlation with measured amount of protein in 24-h
urine (R = 0.976, p < 0.001, SEE = 0.55 g/24 h). In
contrast, correlations of UPCR or UPCR normalized for
BSA, respectively, with measured 24 h urinary protein
excretion, were lower (R = 0.791, p < 0.001, SEE =







PRECISION IQR (P25, P75)
of differences†
ACCURACY
P15 (%) P30 (%)
All subjects (N = 31) mCrCl 0.972*** 8.8 0 4.4 7.9 (-4.3, 3.6) 27 (87)a 30 (97)bcd
4vMDRD 0.935*** 11.4 −8.3 8.9 13.7 (-18.8, -5.2) 8 (26) 25 (81)
CKD-EPI 0.932*** 13.0 −7.0 7.2 12.1 (-15.7, -3.6) 9 (29) 26 (84)
CG-CrCl 0.920*** 14.2 −4.4 7.1 9.0 (-8.7, 0.4) 17 (55) 28 (90)
Male (N = 15) mCrCl 0.958*** 11.3 0.8 7.3 15.5 (-11.5, 4.0) 13 (87) 15 (100)
4vMDRD 0.961*** 9.0 −17.0 17.0 21.9 (-28.7, -6.8) 3 (20) 12 (80)
CKD-EPI 0.967*** 9.2 −8.4 8.4 17.1 (- 23.3, -6.2) 4 (27) 14 (93)
CG-CrCl 0.965*** 9.6 −8.8 8.8 11.2 (-15.5, -4.3) 8 (53) 14 (93)
Female (N = 16) mCrCl 0.967*** 5.9 −0.6 4.2 7.3 (-4.2, 3.1) 15 (94) 15 (94)
4vMDRD 0.915*** 10.8 −5.9 7.4 6.3 (-10.2, -3.9) 5 (31) 11 (69)
CKD-EPI 0.916*** 12.4 −4.8 5.9 6.7 (-8.7, -1.9) 5 (31) 11 (69)
CG-CrCl 0.893*** 14.4 −1.1 4.0 7.6 (-5.6, 1.9) 8 (50) 13 (81)
CrCl > 60 (N = 11) mCrCl 0.677* 10.3 0.7 11 17.8 (-11.5, 6.3) 10 (91) 11 (100)
4vMDRD 0.214º 15.5 −22.0 24.4 22.1 (-34.5, -12.4) 2 (18) 8 (73)
CKD-EPI 0.153º 16.8 −18.4 19.0 23.6 (-25.5, -1.9) 4 (36) 10 (91)
CG-CrCl 0.247º 20.3 −8.1 9.4 13.0 (-17.8, -4.8) 4 (36) 10 (91)
CrCl 30 to 60 (N = 11) mCrCl 0.756** 7.0 −3.8 5.9 7.8 (-5.2, 2.7) 10 (91) 11 (100)
4vMDRD 0.744** 4.7 −8.0 8.0 5.4 (-10.8, -5.4) 4 (36) 9 (82)
CKD-EPI 0.731* 5.0 −7.0 7.0 5.1 (-10.8, -5.7) 3 (27) 9 (82)
CG-CrCl 0.695* 7.1 −3.3 5.1 6.8 (-7.5, -0.6) 6 (55) 11 (100)
CrCl < 30 (N = 9) mCrCl 0.767** 3.9 1.4 1.5 2.3 (-0.2, 2.1) 8 (89) 8 (89)
4vMDRD 0.672* 2.8 −6.2 6.2 3.0 (-7.2, -4.2) 2 (22) 7 (78)
CKD-EPI 0.593º 3.4 −6.4 6.4 4.0 (-8.2, -4.2) 2 (22) 7 (78)
CG-CrCl 0.300º 7.4 −0.6 4.2 6.0 (-4.2, 1.9) 4 (44) 7 (78)
BMI > 30 (N = 8) mCrCl 0.989*** 6.8 0.1 2.7 7.3 (-5.9, 1.4) 7 (88) 8 (100)
4vMDRD 0.876** 21.2 −10.3 16.3 19.7 (-25.5, -5.9) 0 3 (38)
CKD-EPI 0.861** 24.6 −8.8 14.1 16.2 (-22.0, -5.9) 0 6 (75)
CG-CrCl 0.874** 25.5 −6.1 7.1 9.5 (-7.7, 1.8) 4 (93) 7 (88)
BMI > 25 bis 29.9 (N = 16) mCrCl 0.956*** 10.8 −0.4 4.3 8.1 (-4.3, 3.8) 14 (88) 15 (94)
4vMDRD 0.963*** 7.7 −6.8 6.8 10.3 (-14.2, -3.9) 7 (44) 13 (81)
CKD-EPI 0.972*** 7.5 −6.7 6.7 9.0 (-12.0, -3.0) 5 (31) 13 (81)
CG-CrCl 0.963*** 8.0 −3.1 7.8 10.7 (-10.0, 0.7) 9 (56) 14 (88)
BMI < 24.9 (N = 7) mCrCl 0.984*** 6.5 0.8 5.9 (-11, 0.8)†† 7 (100) 7 (100)
4vMDRD 0.983*** 5.6 −11.0 11.0 (-33.0, -5.3)†† 1 (14) 6 (86)
CKD-EPI 0.971*** 8.7 −6.0 6.0 (-26.0, -0.8)†† 3 (43) 7 (100)
CG-CrCl 0.950*** 10.7 −4.2 4.2 (-32.7, 1.8)†† 4 (57) 7 (100)
***p < 0.001; **p < 0.01; *p < 0.05; ºnon significant
†displayed in mL/min/1.73 m2; ††(Minimum, Maximum)
ap < 0.005 vs the three other methods; bp = 0.07 vs 4vMDRD; cp = 0.21 vs CKD-EPI;dp = 0.50 vs CG
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1.28 g/24 h; R = 0.862, p < 0.001, SEE = 1.10 g/24 h,
respectively). The median difference between mea-
sured and calculated amount of 24 h urinary protein
was -0.02 (IQR = 0.20) g/24 h for the BCM based
24 h-creatininuria method. In contrast, calculated
protein excretion from UPCR, normalized or not
normalized for BSA, differed from the total of mea-
sured protein in 24-h urine by median 0.08 g/24 h
(IQR = 0.12) and 0.27 g/24 h (IQR = ±0.63), respect-
ively. Accuracy, analysed as percentage of estimates
lying within 15 % (P15) or 30 % (P30), showed a superior
performance of the BCM based pPU (P15 = 50 %; P30 =
83 %) over protein excretion calculated from UPCR
normalized (P15 = 8 %; P30 = 22 %) and not normalized
(P15 = 17 %; P30 = 61 %) for BSA (p < 0.05, p < 0.001, re-
spectively). Bias and agreement of the different methods
to estimate urinary protein excretion are shown in Fig. 3.
The most striking difference regarding accuracy, however,
could be observed in a subgroup of 11 individuals with
measured 24hU proteinuria above 1000 mg. Whereas in
BCM based pPU P15 showed a high degree of accuracy of
73 % (P30 = 100 %), P15 for UPCR, normalized or not
normalized for BSA, indicated lesser accuracy estimates,
with P15 of 0 for both, and P30 of 0 and 18 %, respectively.
Discussion
In the present study, we demonstrate and confirm that a
model using body cell mass (BCM) determined by tetra-
polar single frequency bioimpedance analysis (BIA) pro-
vides accurate estimations of creatinine clearance over a
wide range of renal function, both in patients with
nephropathy and in healthy individuals. This BCM based
model proved to be superior to estimation formulas such
as the Cockcroft-Gault, 4vMDRD or CKD-EPI formulas
that are solely derived from plasma creatinine mea-
surements. Moreover, this approach is clearly less cumber-
some than determination of the clinical gold standard of
creatinine clearance derived from 24 h urine collection. In
Fig. 1 Correlation plots of GFR prediction by different methods with 24hU-CrCl (units of x- and y-axis mL/min/1.73 m2). a mCrCl: y = 0.95x + 2.19,
SEE = 8.83; R = 0.97, p < 0.001. b 4vMDRD-GFR: y = 0.79x + 0.84, SEE = 11.37; R = 0.93, p < 0.001. c CKD-EPI-GFR: y = 0.88x -1.53, SEE = 12.99; R = 0.93,
p < 0.001. d CG-CrCl: y = 0.88x +3.26, SEE = 14.24; R = 0.92, p < 0.001
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addition to previous studies using a similar concept, we
have extended the model to predict 24-h protein excretion
from a single spot urine [22, 23].
Estimation of excretory renal function in clinical prac-
tice is usually based on estimation methods derived from
plasma creatinine measurements. The latter – and thereby
the accuracy of these methods regarding GFR determin-
ation – is affected not only by its renal elimination, but
also its production, which depends on several factors.
Among those, the far most important are muscle mass,
and, to a much lesser extent, nutritional aspects. Finally,
age, gender, ethnicity and genetic variability may affect
creatinine production unrelated to muscle mass.
BIA technology has been shown previously to provide
accurate determination of body composition in various
stages of CKD, including patients undergoing mainten-
ance hemodialysis [30–33]. As demonstrated by Donadio
et al., body cell mass determined by tetrapolar single
frequency BIA correlated best with urinary creatinine
excretion [21–23]. BCM, extracellular (ECM) and fat
mass (FM) constitute the three body compartments as
described in detail elsewhere [27]. Lean body mass
(LBM), which we obtained from the skinfold measure-
ments method, can be used synonymously with FFM for
our purposes. BCM in contrast is defined as the total
mass of all cells in the body that constitutes all metabol-
ically active tissues and, therefore, unlike FFM or LBM,
excludes extracellular mass (ECM). Hence, it most
accurately reflects the total of all muscle fiber containing
cells, including both skeletal and smooth muscle cells,
thereby explaining the good correlation with excreted
creatinine in our study as well as in those mentioned
above. In contrast, other anthropometric parameters like
waist/hip ratio or skin fold based measurements did not
contribute substantially to the model predicting CrCl.
Likewise, tetrapolar BIA performed substantially better
compared to the handheld BIA device used for compari-
son. Like others, we developed and validated our model
Fig. 2 Bland-Altman-Plots of GFR-prediction by different methods in comparison with 24hU-CrCl (units of x- and y-axis mL/min/1.73 m2). a mCrCl:
bias (mean difference) = -0.6, limits of agreement (LoA) = -18.0, 16.8 (dashed lines), 95 % confidence interval of upper and lower LoA (thin lines).
b 4vMDRD-GFR: bias = -11.7, LoA = -38.6, 15.3. c CKD-EPI-GFR: bias = -8.7, LoA = -35.3, 17.9. d CG-CrCl: bias = -3.9, LoA = -32.7, 25.0
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by using training and a validation group [22, 23]. In
contrast to previous studies, however, additional vari-
ables were measured and tested to be incorporated into
our prediction formula, resulting in a regression model
containing BCM and gender.
Unstratified, the BIA derived method yielded the best
results of concordance and accuracy with the measured
CrCl among all tested models. Stratified for body weight,
the BIA based prediction formula seemed to perform
best in subjects with BMI > 30 kg/m2. Likewise, the
newly developed prediction method excelled in the sub-
group of patients with measured CrCl > 60 mL/min/
1.73 m2. However, even in lower range strata of CrCl or
BMI, the model was overall superior to all other estima-
tion methods. With regard to the statistical outlier patient
with characteristics reflecting ‘sarcopenic obesity’, it seems
that the BIA based GFR estimation method outperforms
the other equations most obviously. The substantial
impact of inclusion versus exclusion of this outlier patient
on correlation coefficients and SEE has to be interpreted
in context of the small subgroups.
Although a correct 24 h urine collection remains the
gold standard to quantify proteinuria, urinary protein/
creatinine ratio is broadly accepted (UPCR) for assessing
and monitoring the course of proteinuric nephropathy.
With the denominator of UPCR being expressed in
grams of creatinine, the nominator is usually considered
to reflect the amount of 24 h urinary protein excretion,
as the average individual 24-h creatinine excretion for the
population is approximately 1000 mg/day per 1.73 m2.
Considering the fact that some individuals’ creatinine ex-
cretion per day will markedly differ from 1 g (e.g. muscle
mass differing from average or due to changing body
composition), it appears worthwhile to establish a better
method to more accurately estimate proteinuria. Towards
this aim, using UPCR from a spot urine sample extrapo-
lated to estimated 24 h urinary protein excretion based on
24 h-creatininuria derived from BIA measurement, signifi-
cantly improves the quantification of 24 h urinary protein
excretion. However, this approach, too, does not account
for circadian variability in urinary protein excretion.
Several limitations apply to our findings. First, all
methods examined were compared to measured CrCl
rather than GFR. Thus, for the 4vMDRD and CKD-EPI
formulas, which refer to GFR, systematic underestimation
to measured CrCl results, which partly explains the lower
accuracy and larger bias of these estimates. Nevertheless,
comparison between the BCM based method and the
common estimation formulas referring to measured CrCl
not only revealed no systematic difference in the former
in contrast to the latter, but also less variation. Second, it
could be argued that methods to predict excretory kidney
function should be evaluated against the gold standard for
measured GFR, such as radionuclide techniques. However,
we deliberately chose CrCl from timed urine collection in-
stead, as this represents the universal clinical standard for
Table 6 Validation group: Correlations, bias, precision and accuracy of the different GFR prediction methods and measured 24hU-CrCl







PRECISION IQR (P25, P75)
of differences†
ACCURACY
P15 (%) P30 (%)
All subjects (N = 30) mCrCl 0.972*** 9.0 0.1 4.3 6.9 (-4.4, 2.5) 27 (90)a 30 (100)bcd
4vMDRD 0.974*** 8.7 −8.6 8.6 14.4 (-19.7, -5.3) 8 (27) 17 (57)
CKD-EPI 0.974*** 8.7 −7.1 7.1 12.9 (-17.1, -4.2) 9 (30) 17 (57)
CG-CrCl 0.971*** 9.3 −4.8 6.6 9.1 (-9.0, 0.1) 17 (55) 28 (93)
Female (N = 15) mCrCl 0.952*** 5.6 −0.6 1.8 6.3 (-4.2, 2.1) 14 (93) 14 (93)
4vMDRD 0.951*** 4.8 −6.4 6.4 6.1 (-10.3, -4.2) 5 (33) 11 (73)
CKD-EPI 0.929*** 6.7 −5.3 5.3 6.2 (-8.8, -2.7) 5 (33) 11 (73)
CG-CrCl 0.952*** 6.7 −1.6 2.8 8.0 (-6.2, 1.8) 8 (53) 13 (87)
CrCl > 60 (N = 10) mCrCl 0.638* 14.0 −0.4 11.5 15.3 (-11.7, 3.5) 9 (90) 10 (100)
4vMDRD 0.668* 13.6 −23.2 23.2 21.4 (-35.3, -13.9) 2 (20) 8 (80)
CKD-EPI 0.660* 13.7 −18.7 18.7 22.3 (-25.8, -3.5) 4 (40) 10 (100)
CG-CrCl 0.771** 11.6 −8.7 8.7 14.9 (-20.6, -5.7) 4 (40) 10 (100)
BMI > 30 (N = 7) mCrCl 0.995*** 5.2 −0.4 1.5 (-15.5, 1.5)†† 7 (100) 7 (100)
4vMDRD 0.991*** 7.4 −10.5 10.5 (-42.0, -4.2)†† 0 3 (43)
CKD-EPI 0.995*** 5.4 −9.1 9.1 (-34.0, -4.2)†† 0 6 (86)
CG-CrCl 0.987*** 8.9 −7.1 7.1 (-26.6, 6.1)†† 4 (57) 7 (100)
***p < 0.001; **p < 0.01; *p < 0.05;
†displayed in mL/min/1.73 m2; ††(Minimum, Maximum)
ap < 0.005 vs the three other methods; bp = 0.12 vs 4vMDRD; cp = 0.34 vs CKD-EPI; dp = 0.8 vs CG
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routine determination of measured excretory renal func-
tion [34, 35]. Moreover, pharmaceutical dosing informa-
tion is traditionally given for CrCl strata and in reference
to the Cockcroft-Gault formula for its estimation [36].
Third, a new GFR prediction method based on serum
cystatin C has recently been published [37]. In our study,
we did not examine cystatin C, therefore, it could not be
compared to our model. Cystatin C, which is less
dependent on muscle mass than creatinine, may be a use-
ful marker for kidney function in subjects with body com-
position outside of the normal range, too. Fourth, all
methods to determine renal function based on creatinine,
including ours, are limited by its tubular secretion, which
is proportionally higher in the lower range of excretory
kidney function (e.g. GFR below 20 mL/min/1.73 m2).
However, this limitation is usually outweighed in subjects
with abnormal body composition. Furthermore, it has to
be emphasized that the investigated population exclusively
consisted of Caucasians, formally limiting the extrapolation
of our findings to individuals of other ethnicity. Finally, the
BIA technology applied in our study used single frequency
rather than multifrequency measurements, which, theoret-
ically, could have resulted in even better prediction of body
compartments, and, thus, estimated CrCl.
Conclusion
In summary and conclusion, the method presented herein
to predict creatinine clearance and urinary protein excre-
tion based on a model using estimated urinary creatinine
excretion determined by measurement of body cell mass
by bioimpedance (BIA) technique has proven to be both
accurate and convenient to quantify renal function in
normal and diseased states. This method may become
particularly helpful for the evaluation of patients with
borderline renal insufficiency and/or with abnormal body
composition as well as in ethnical groups other than those
used for development and validation of the established
estimation formulas.
Fig. 3 Bland-Altman-Plots of 24 h urinary protein excretion prediction in comparison with measured 24 h urinary protein excretion (24 h-PU)
(units of x- and y-axis g/24 h). a estimated 24 h urinary protein excretion by m24hU-Cr base: Bias (mean difference) = 0.1 g/24 h, LoA = -1.1, 1.4
g/24 h (dashed lines), 95 % confidence interval of upper and lower LoA (thin lines). b estimated 24 h urinary protein excretion by UPCR: Bias = -0.3
g/24 h, LoA = -2.5, 1.9 g/24 h. c estimated 24 h urinary protein excretion by UPCR/1.73 m2: Bias = -0.4 g/24 h, LoA = -3.1, 2.2 g/24 h
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